Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:TECH
- CUSIP: 87837710
- Web: www.techne-corp.com
Capitalization:- Market Cap: $4.54627 billion
- Outstanding Shares: 37,382,000
Average Prices:- 50 Day Moving Avg: $119.11
- 200 Day Moving Avg: $112.10
- 52 Week Range: $95.68 - $124.00
P/E:- Trailing P/E Ratio: 59.96
- Foreward P/E Ratio: 29.69
- P/E Growth: 2.97
Sales & Book Value:- Annual Revenue: $563 million
- Price / Sales: 8.08
- Book Value: $25.42 per share
- Price / Book: 4.79
Dividend:- Annual Dividend: $1.28
- Dividend Yield: 1.1%
Profitability:- EBIDTA: $186.35 million
- Net Margins: 12.93%
- Return on Equity: 14.19%
- Return on Assets: 8.43%
Debt:- Debt-to-Equity Ratio: 0.36%
- Current Ratio: 2.57%
- Quick Ratio: 2.12%
Misc:- Average Volume: 156,277 shs.
- Beta: 0.78
- Short Ratio: 11.79
Frequently Asked Questions for Bio-Techne Corp (NASDAQ:TECH)
What is Bio-Techne Corp's stock symbol?
Bio-Techne Corp trades on the NASDAQ under the ticker symbol "TECH."
How often does Bio-Techne Corp pay dividends? What is the dividend yield for Bio-Techne Corp?
Bio-Techne Corp announced a quarterly dividend on Wednesday, August 9th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.32 per share on Friday, September 1st. This represents a $1.28 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date is Wednesday, August 16th. View Bio-Techne Corp's Dividend History.
How were Bio-Techne Corp's earnings last quarter?
Bio-Techne Corp (NASDAQ:TECH) posted its quarterly earnings results on Tuesday, August, 8th. The company reported $1.09 EPS for the quarter, beating the Zacks' consensus estimate of $0.99 by $0.10. The firm earned $156.60 million during the quarter, compared to analyst estimates of $150.25 million. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.19%. The firm's revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 EPS. View Bio-Techne Corp's Earnings History.
When will Bio-Techne Corp make its next earnings announcement?
Where is Bio-Techne Corp's stock going? Where will Bio-Techne Corp's stock price be in 2017?
5 brokerages have issued twelve-month price targets for Bio-Techne Corp's shares. Their predictions range from $122.00 to $132.00. On average, they anticipate Bio-Techne Corp's stock price to reach $126.33 in the next twelve months. View Analyst Ratings for Bio-Techne Corp.
Who are some of Bio-Techne Corp's key competitors?
Some companies that are related to Bio-Techne Corp include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Icon Plc (ICLR), INC Research Holdings (INCR), United Therapeutics Corporation (UTHR), Galapagos NV (GLPG), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).
Who are Bio-Techne Corp's key executives?
Bio-Techne Corp's management team includes the folowing people:
- Robert V. Baumgartner CPA, Independent Chairman of the Board
- Charles R. Kummeth, President, Chief Executive Officer, Director
- Roger C. Lucas Ph.D., Independent Vice Chairman of the Board
- James T. Hippel, Chief Financial Officer, Senior Vice President
- Brenda S. Furlow J.D., Senior Vice President, General Counsel, Secretary
- David Eansor, Senior Vice President - Biotechnology
- Robert Gavin, Senior Vice President-Protein Platforms
- Kevin S. Gould, Senior Vice President-Clinical Controls
- J. Fernando Bazan Ph.D., Chief Technology Officer
- Charles A. Dinarello M.D., Independent Director
Who owns Bio-Techne Corp stock?
Bio-Techne Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.54%), Vanguard Group Inc. (8.15%), Atlanta Capital Management Co. L L C (5.25%), Neuberger Berman Group LLC (4.92%), Bamco Inc. NY (4.02%) and Janus Henderson Group PLC (3.18%). Company insiders that own Bio-Techne Corp stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for Bio-Techne Corp.
Who sold Bio-Techne Corp stock? Who is selling Bio-Techne Corp stock?
Bio-Techne Corp's stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Macquarie Group Ltd., Royce & Associates LP, Neuberger Berman Group LLC, Renaissance Technologies LLC, GSA Capital Partners LLP, Northern Trust Corp and Riverbridge Partners LLC. Company insiders that have sold Bio-Techne Corp stock in the last year include Charles A Dinarello, Karen A Holbrook and Roger C Lucas. View Insider Buying and Selling for Bio-Techne Corp.
Who bought Bio-Techne Corp stock? Who is buying Bio-Techne Corp stock?
Bio-Techne Corp's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, American Century Companies Inc., Koch Industries Inc., Schroder Investment Management Group, SG Capital Management LLC, Commonwealth Bank of Australia, Public Employees Retirement Association of Colorado and Lord Abbett & CO. LLC. View Insider Buying and Selling for Bio-Techne Corp.
How do I buy Bio-Techne Corp stock?
Shares of Bio-Techne Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Techne Corp's stock price today?
One share of Bio-Techne Corp stock can currently be purchased for approximately $121.72.
MarketBeat Community Rating for Bio-Techne Corp (NASDAQ TECH)MarketBeat's community ratings are surveys of what our community members think about Bio-Techne Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Bio-Techne Corp (NASDAQ:TECH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $126.33 (3.79% upside) |
Analysts' Ratings History for Bio-Techne Corp (NASDAQ:TECH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/30/2017 | Deutsche Bank AG | Set Price Target | Buy | $132.00 | Medium |  |
| 7/13/2017 | Wells Fargo & Company | Initiated Coverage | Market Perform -> Market Perform | | Low | |
| 5/3/2017 | Citigroup Inc. | Reiterated Rating | Buy | $115.00 -> $125.00 | Low | |
| 3/27/2017 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | | High | |
| 11/10/2016 | Leerink Swann | Initiated Coverage | Outperform | $122.00 | N/A | |
| 8/18/2016 | Robert W. Baird | Boost Price Target | Outperform | $115.00 -> $116.00 | N/A | |
| 11/2/2015 | Craig Hallum | Lower Price Target | Buy | $125.00 -> $110.00 | N/A | |
| 10/29/2015 | Stephens | Downgrade | Overweight -> Equal Weight | | N/A | |
(Data available from 9/19/2015 forward)
Earnings History for Bio-Techne Corp (NASDAQ:TECH)Earnings History by Quarter for Bio-Techne Corp (NASDAQ TECH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | $0.88 | | | | | N/A | |
| 8/8/2017 | Q4 2017 | $0.99 | $1.09 | $150.25 million | $156.60 million | View | Listen | |
| 5/2/2017 | Q3 2017 | $0.93 | $0.97 | $142.83 million | $144.04 million | View | Listen | |
| 2/7/2017 | Q217 | $0.85 | $0.81 | $134.74 million | $131.80 million | View | Listen | |
| 10/31/2016 | Q117 | $0.79 | $0.84 | $127.47 million | $130.60 million | View | Listen | |
| 8/17/2016 | Q416 | $0.96 | $0.92 | $129.23 million | $134.80 million | View | Listen | |
| 5/3/2016 | Q316 | $0.89 | $1.01 | $122.65 million | $131.00 million | View | N/A | |
| 2/2/2016 | Q216 | $0.82 | $0.88 | $118.59 million | $120.90 million | View | N/A | |
| 10/28/2015 | Q1 | $0.85 | $0.79 | $116.91 million | $12.40 million | View | Listen | |
| 8/6/2015 | Q415 | $0.86 | $0.87 | $116.85 million | $117.70 million | View | N/A | |
| 5/5/2015 | Q315 | $0.91 | $0.86 | $119.30 million | $114.20 million | View | N/A | |
| 2/3/2015 | Q215 | $0.86 | $0.89 | $112.73 million | $111.90 million | View | N/A | |
| 10/28/2014 | Q115 | $0.87 | $0.85 | $108.65 million | $108.50 million | View | N/A | |
| 8/11/2014 | Q414 | $0.85 | $0.88 | $91.80 million | $92.50 million | View | N/A | |
| 4/28/2014 | Q314 | $0.89 | $0.94 | $92.50 million | $95.60 million | View | N/A | |
| 2/4/2014 | Q214 | $0.80 | $0.75 | $84.79 million | $84.00 million | View | N/A | |
| 10/29/2013 | Q114 | $0.80 | $0.83 | $82.36 million | $85.70 million | View | N/A | |
| 8/6/2013 | Q4 2013 | $0.83 | $0.82 | $79.71 million | $79.50 million | View | N/A | |
| 4/30/2013 | Q3 2013 | $0.90 | $0.88 | $84.00 million | $81.00 million | View | N/A | |
| 2/5/2013 | Q2 2013 | $0.77 | $0.74 | $76.40 million | $75.10 million | View | N/A | |
| 10/23/2012 | | $0.79 | $0.75 | | | View | N/A | |
| 7/31/2012 | | $0.85 | $0.80 | | | View | N/A | |
| 5/1/2012 | | $0.89 | $0.90 | | | View | N/A | |
| 1/31/2012 | | $0.79 | $0.76 | | | View | N/A | |
| 10/25/2011 | | $0.84 | $0.81 | | | View | N/A | |
| 8/2/2011 | | $0.76 | $0.76 | | | View | N/A | |
| 5/3/2011 | | $0.80 | $0.84 | | | View | N/A | |
| 2/1/2011 | | $0.68 | $0.71 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Bio-Techne Corp (NASDAQ:TECH)2017 EPS Consensus Estimate: $3.49
2018 EPS Consensus Estimate: $3.76
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.76 | $0.81 | $0.78 |
| Q2 2017 | 3 | $0.81 | $0.85 | $0.83 |
| Q3 2017 | 3 | $0.90 | $0.96 | $0.93 |
| Q4 2017 | 3 | $0.93 | $0.98 | $0.95 |
| Q1 2018 | 1 | $0.88 | $0.88 | $0.88 |
| Q2 2018 | 2 | $0.82 | $0.89 | $0.86 |
| Q3 2018 | 1 | $0.98 | $0.98 | $0.98 |
| Q4 2018 | 2 | $1.02 | $1.07 | $1.05 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Bio-Techne Corp (NASDAQ:TECH)| Most Recent Dividend: | 9/1/2017 |
| Annual Dividend: | $1.28 |
| Dividend Yield: | 1.05% |
| Payout Ratio: | 65.98% (Trailing 12 Months of Earnings)
34.41% (Based on This Year's Estimates)
31.22% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Bio-Techne Corp (NASDAQ TECH)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/9/2017 | Quarterly | $0.32 | 1.1% | 8/16/2017 | 8/18/2017 | 9/1/2017 |
| 5/2/2017 | quarterly | $0.32 | 1.15% | 5/17/2017 | 5/19/2017 | 6/2/2017 |
| 2/7/2017 | quarterly | $0.32 | 1.27% | 2/15/2017 | 2/17/2017 | 3/3/2017 |
| 11/1/2016 | Quarterly | $0.32 | | 11/9/2016 | 11/14/2016 | 11/28/2016 |
| 8/17/2016 | quarterly | $0.32 | | 8/25/2016 | 8/29/2016 | 9/12/2016 |
| 5/3/2016 | quarterly | $0.32 | 1.27% | 5/11/2016 | 5/13/2016 | 5/27/2016 |
| 2/2/2016 | quarterly | $0.32 | 1.48% | 2/10/2016 | 2/12/2016 | 2/26/2016 |
| 10/29/2015 | quarterly | $0.32 | 1.45% | 11/10/2015 | 11/13/2015 | 11/27/2015 |
| 8/6/2015 | quarterly | $0.32 | 1.18% | 8/13/2015 | 8/17/2015 | 8/28/2015 |
| 5/5/2015 | quarterly | $0.32 | 1.31% | 5/11/2015 | 5/15/2015 | 5/29/2015 |
| 2/3/2015 | quarterly | $0.32 | 1.4% | 2/11/2015 | 2/13/2015 | 2/27/2015 |
| 10/30/2014 | quarterly | $0.32 | 1.41% | 11/6/2014 | 11/10/2014 | 11/24/2014 |
| 8/11/2014 | quarterly | $0.31 | 1.31% | 8/19/2014 | 8/21/2014 | 8/29/2014 |
| 4/28/2014 | quarterly | $0.31 | 1.37% | 5/7/2014 | 5/9/2014 | 5/23/2014 |
| 2/4/2014 | quarterly | $0.31 | 1.48% | 2/12/2014 | 2/14/2014 | 2/28/2014 |
| 10/31/2013 | quarterly | $0.31 | 1.4% | 11/7/2013 | 11/12/2013 | 11/25/2013 |
| 8/6/2013 | quarterly | $0.30 | 1.62% | 8/14/2013 | 8/16/2013 | 8/31/2013 |
| 4/30/2013 | quarterly | $0.30 | 1.86% | 5/8/2013 | 5/10/2013 | 5/24/2013 |
| 2/5/2013 | quarterly | $0.30 | 1.74% | 2/13/2013 | 2/15/2013 | 3/1/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Bio-Techne Corp (NASDAQ:TECH)Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 98.43%
Insider Trades by Quarter for Bio-Techne Corp (NASDAQ:TECH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/8/2017 | Roger C Lucas | Director | Sell | 100 | $120.94 | $12,094.00 | |
| 9/6/2017 | Karen A Holbrook | Director | Sell | 1,059 | $121.73 | $128,912.07 | |
| 8/10/2017 | Roger C Lucas | Director | Sell | 100 | $114.30 | $11,430.00 | |
| 7/10/2017 | Roger C Lucas | Director | Sell | 100 | $116.86 | $11,686.00 | |
| 6/9/2017 | Roger C Lucas | Director | Sell | 100 | $113.62 | $11,362.00 | |
| 5/31/2017 | Charles A Dinarello | Director | Sell | 5,000 | $111.37 | $556,850.00 | |
| 5/25/2017 | Karen A Holbrook | Director | Sell | 5,000 | $111.15 | $555,750.00 | |
| 5/10/2017 | Roger C Lucas | Director | Sell | 100 | $110.59 | $11,059.00 | |
| 4/10/2017 | Roger C Lucas | Director | Sell | 100 | $101.15 | $10,115.00 | |
| 1/10/2017 | Roger C Lucas | Director | Sell | 100 | $103.57 | $10,357.00 | |
| 11/29/2016 | Karen A Holbrook | Director | Sell | 1,000 | $106.73 | $106,730.00 | |
| 11/16/2016 | Roger C Lucas | Director | Sell | 100 | $105.75 | $10,575.00 | |
| 9/21/2016 | Roger C Lucas | Director | Sell | 100 | $108.91 | $10,891.00 | |
| 9/8/2016 | John L Higgins | Director | Sell | 1,700 | $109.83 | $186,711.00 | |
| 9/8/2016 | Kevin S. Gould | SVP | Sell | 524 | $110.50 | $57,902.00 | |
| 9/2/2016 | Robert V Baumgartner | Director | Sell | 6,467 | $107.17 | $693,068.39 | |
| 8/24/2016 | Robert V Baumgartner | Director | Sell | 3,533 | $107.10 | $378,384.30 | |
| 8/17/2016 | Roger C. Lucas | Director | Sell | 100 | $113.70 | $11,370.00 | |
| 7/20/2016 | Roger C Lucas | Director | Sell | 100 | $111.03 | $11,103.00 | |
| 6/15/2016 | Roger C Lucas | Director | Sell | 100 | $112.15 | $11,215.00 | |
| 5/18/2016 | Roger C Lucas | Director | Sell | 100 | $102.53 | $10,253.00 | |
| 5/9/2016 | Charles A Dinarello | Director | Sell | 5,000 | $101.91 | $509,550.00 | |
| 5/6/2016 | Roger C Lucas | Director | Sell | 500 | $100.24 | $50,120.00 | |
| 4/20/2016 | Roger C Lucas | Director | Sell | 100 | $92.40 | $9,240.00 | |
| 3/16/2016 | Roger C Lucas | Director | Sell | 100 | $92.90 | $9,290.00 | |
| 2/5/2016 | Roger C. Lucas | Director | Sell | 5,000 | $83.68 | $418,400.00 | |
| 8/13/2015 | Roger C Lucas | Director | Sell | 5,000 | $106.01 | $530,050.00 | |
| 6/8/2015 | Randolph C Steer | Director | Sell | 1,000 | $99.39 | $99,390.00 | |
| 2/19/2015 | Howard V Oconnell | Director | Sell | 5,000 | $95.78 | $478,900.00 | |
| 12/10/2014 | Karen A Holbrook | Director | Sell | 1,000 | $92.40 | $92,400.00 | |
| 12/9/2014 | Kevin J Reagan | VP | Sell | 3,591 | $89.35 | $320,855.85 | |
| 12/8/2014 | Charles A Dinarello | Director | Sell | 3,000 | $90.44 | $271,320.00 | |
| 8/14/2014 | Karen A Holbrook | Director | Sell | 5,000 | $95.54 | $477,700.00 | |
| 5/7/2014 | Howard Oconnell | Director | Sell | 5,000 | $91.00 | $455,000.00 | |
| 3/4/2014 | Karen Holbrook | Director | Sell | 5,000 | $89.83 | $449,150.00 | |
| 2/27/2014 | Randolph Steer | Director | Sell | 5,000 | $88.78 | $443,900.00 | |
| 11/13/2013 | Randolph Steer | Director | Sell | 15,000 | $86.20 | $1,293,000.00 | |
| 11/8/2013 | Robert Baumgartner | Director | Sell | 10,000 | $87.00 | $870,000.00 | |
| 11/4/2013 | Roger C Lucas | Director | Sell | 10,000 | $87.64 | $876,400.00 | |
| 5/6/2013 | Howard V Oconnell | Director | Buy | 2,361 | $65.00 | $153,465.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Bio-Techne Corp (NASDAQ:TECH)
Latest Headlines for Bio-Techne Corp (NASDAQ:TECH)
| Source: |
|
| Date | Headline |
|---|
 | Bio-Techne Corp (TECH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 16 at 8:34 AM |
 | ETFs with exposure to Bio-Techne Corp. : September 14, 2017
finance.yahoo.com - September 14 at 11:05 AM |
 | Bio-Techne CEO Charles Kummeth's compensation jumps to $9.1M
www.bizjournals.com - September 13 at 10:00 AM |
| Bio-Techne Introduces a New Luminex Multi-analyte Assay Kit
finance.yahoo.com - September 13 at 10:00 AM |
| Insider Selling: Bio-Techne Corp (TECH) Director Sells 100 Shares of Stock
www.americanbankingnews.com - September 12 at 8:24 PM |
| Bio-Techne Corp. :TECH-US: Earnings Analysis: 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 12 at 10:47 AM |
| Contrasting Bio-Techne Corp (TECH) and its Competitors
www.americanbankingnews.com - September 12 at 12:28 AM |
| Karen A. Holbrook Sells 1,059 Shares of Bio-Techne Corp (TECH) Stock
www.americanbankingnews.com - September 8 at 8:40 PM |
| Featured Company News - Bio-Techne Acquires Trevigen in an All-cash Deal
finance.yahoo.com - September 8 at 9:12 AM |
| Bio-Techne Releases A Highly Sensitive and Specific Serological Assay to Detect Zika Virus Infections
finance.yahoo.com - September 7 at 9:46 AM |
 | BRIEF-Bio-Techne acquires Trevigen Inc
www.reuters.com - September 6 at 9:06 AM |
 | Bio-Techne buys Trevigen in all-cash deal
seekingalpha.com - September 6 at 7:35 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne Corporation - TECH
finance.yahoo.com - August 31 at 10:51 AM |
| Deutsche Bank AG Reiterates $132.00 Price Target for Bio-Techne Corp (TECH)
www.americanbankingnews.com - August 30 at 10:34 PM |
| Bio-Techne To Present At The Wells Fargo Healthcare Conference
finance.yahoo.com - August 29 at 8:33 AM |
| Brokerages Anticipate Bio-Techne Corp (TECH) Will Post Quarterly Sales of $142.75 Million
www.americanbankingnews.com - August 26 at 7:26 PM |
| Bio-Techne Corp (TECH) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - August 24 at 12:14 AM |
| Bio-Techne Corp to Post FY2019 Earnings of $3.99 Per Share, William Blair Forecasts (TECH)
www.americanbankingnews.com - August 23 at 3:22 PM |
| Bio-Techne To Present At The Baird 2017 Global Healthcare Conference
finance.yahoo.com - August 23 at 12:28 PM |
| William Blair Weighs in on Bio-Techne Corp's FY2018 Earnings (TECH)
www.americanbankingnews.com - August 22 at 1:58 PM |
| Bio-Techne Corp (TECH) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 22 at 8:34 AM |
| Google's Alphabet passes Facebook as hedge fund favorite
finance.yahoo.com - August 20 at 11:05 PM |
| Bio-Techne Corp. – Value Analysis (NASDAQ:TECH) : August 19, 2017
finance.yahoo.com - August 19 at 8:09 AM |
| Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer
finance.yahoo.com - August 18 at 7:47 AM |
| Bio-Techne Corp (TECH) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 15 at 11:16 AM |
| Roger C. Lucas Sells 100 Shares of Bio-Techne Corp (NASDAQ:TECH) Stock
www.americanbankingnews.com - August 15 at 12:16 AM |
| Bio-Techne Corp Forecasted to Post Q2 2018 Earnings of $0.82 Per Share (TECH)
www.americanbankingnews.com - August 14 at 7:38 AM |
| Bio-Techne Corp (TECH) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - August 12 at 7:54 AM |
| See what the IHS Markit Score report has to say about Bio-Techne Corp.
finance.yahoo.com - August 10 at 9:31 PM |
| Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
finance.yahoo.com - August 10 at 4:28 PM |
| Bio-Techne Corp Declares Quarterly Dividend of $0.32 (TECH)
www.americanbankingnews.com - August 10 at 2:20 PM |
| BRIEF-Bio-Techne Q4 adjusted earnings per share $1.09
www.reuters.com - August 10 at 8:40 AM |
| Bio-Techne Corp (TECH) PT Raised to $132.00 at Deutsche Bank AG
www.americanbankingnews.com - August 9 at 2:08 PM |
| Bio-Techne Releases Fourth Quarter Fiscal 2017 Results
finance.yahoo.com - August 9 at 8:08 AM |
| Bio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : August 8, 2017
finance.yahoo.com - August 9 at 8:08 AM |
| Edited Transcript of TECH earnings conference call or presentation 8-Aug-17 1:00pm GMT
finance.yahoo.com - August 9 at 8:08 AM |
| Bio-Techne Corp (NASDAQ:TECH) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 1:52 PM |
| Zacks: Analysts Expect Bio-Techne Corp (NASDAQ:TECH) Will Post Quarterly Sales of $149.49 Million
www.americanbankingnews.com - August 7 at 7:44 AM |
| Bio-Techne Corp (TECH) Downgraded by BidaskClub
www.americanbankingnews.com - August 5 at 10:58 AM |
 | Should You Buy Bio-Techne (TECH) Ahead of Earnings?
www.zacks.com - August 4 at 8:55 AM |
| ETFs with exposure to Bio-Techne Corp. : August 1, 2017
finance.yahoo.com - August 2 at 7:41 AM |
| Bio-Techne Corp (TECH) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:31 AM |
| Bio-Techne Corp (NASDAQ:TECH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 28 at 8:29 AM |
| Bio-Techne Corp (TECH) Lowered to Hold at BidaskClub
www.americanbankingnews.com - July 16 at 9:32 PM |
| Bio-Techne Corp (TECH) Expected to Announce Quarterly Sales of $149.49 Million
www.americanbankingnews.com - July 16 at 7:54 AM |
| Zacks: Analysts Expect Bio-Techne Corp (NASDAQ:TECH) Will Announce Earnings of $0.90 Per Share
www.americanbankingnews.com - July 14 at 10:28 PM |
| ETFs with exposure to Bio-Techne Corp. : July 13, 2017
finance.yahoo.com - July 14 at 9:03 AM |
| Bio-Techne To Host Conference Call On August 8, 2017 To Announce Fourth Quarter Financial Results
finance.yahoo.com - July 13 at 10:16 AM |
| Bio-Techne Corp (TECH) Director Roger C. Lucas Sells 100 Shares
www.americanbankingnews.com - July 12 at 8:44 PM |
| Bio-Techne Corp (NASDAQ:TECH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 6 at 2:00 PM |
Bio-Techne Corp (TECH) Chart for Tuesday, September, 19, 2017
